Exploring the impact of ursodeoxycholic acid therapy on COVID‐19 in a real‐word setting
Christophe Corpechot, Marie Verdoux, Marie Frank‐soltysiak, Jean‐charles Duclos‐vallée, Lamiae Grimaldi
Journal of Medical Virology, doi:10.1002/jmv.29418
Recent data suggest that ursodeoxycholic acid (UDCA) therapy may reduce susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and even improve clinical outcomes when coronavirus disease-2019 (COVID-19) was diagnosed. However, clinical evidence of UDCA's ability to prevent severe forms of COVID-19 remains limited and contradictory. We evaluated the association between UDCA exposure and the risk of hospitalization for COVID-19 in a large multicenter population of patients with chronic liver disease (CLD) followed during the pandemic period before vaccination. An exposed/unexposed cohort study and a nested case-control study were performed. The primary endpoint was severe COVID-19, defined as SARS-CoV2 infection requiring hospitalization. The secondary endpoint was COVID-19-associated intensive care unit (ICU) admission or death. Adjusted odds ratios (aOR) and their confidence intervals (CI) were determined after controlling for age, gender, comorbidities at risk for COVID-19, severity of CLD, and prior hospitalizations. A total of 10 147 patients, including 1322 exposed and 8825 not exposed to UDCA, totaling 21 867 person-years of follow-up, were included in the cohort analysis, while 88 patients hospitalized for COVID-19 and 840 matched controls were eligible for the nested case-control analysis. In both analyses, exposure to UDCA was not associated with a significant reduction in the risk of hospitalization for COVID-19, with aOR (95% confidence interval) values of 0.48 (0.20-1.19) and 0.93 (0.26-3.29), respectively. Furthermore, there was no significant reduction in the risk of ICU admission or death. In this large population of patients with CLD, UDCA exposure was not associated with a reduced risk of severe COVID-19.
AUTHOR CONTRIBUTIONS Christophe Corpechot, Jean-Charles Duclos-Vallée, and Lamiae Grimaldi conceived and designed the study. Data were extracted and analyzed by Marie Verdoux and Lamiae Grimaldi. The first draft of the study was written by Christophe Corpechot and Lamiae Grimaldi. All authors participated in the revision of the manuscript, approved the submitted versions, and confirmed the accuracy and completeness of the data and the fidelity of the analysis to the protocol.
CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest.
SUPPORTING INFORMATION Additional supporting information can be found online in the Supporting Information section at the end of this article.
References
Ampuero, Lucena, Hernández-Guerra, Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes, Gut,
doi:10.1136/gutjnl-2021-325700Brat, Weber, Gehlenborg, International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium, npj Digit Med
Brevini, Maes, Webb, FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2, Nature
Colapietro, Angelotti, Masetti, Ursodeoxycholic acid does not improve COVID-19 outcome in hospitalized patients, Viruses
Daniel, Serre, Orlova, Bréant, Paris et al., Initializing a hospital-wide data quality program. The AP-HP experience, Comput Methods Programs Biomed
Hu, Zhang, Huang, Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study, QJM,
doi:10.1093/qjmed/hcad254John, Bastaich, Webb, Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis, J Intern Med
Li, Zhu, Cui, Lin, Li, Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease, Front Cell Infect Microbiol
Liu, Wang, Ursodeoxycholic acid administration did not reduce susceptibility to SARS-CoV-2 infection in children, Liver Int
Marrone, Covino, Merra, Ursodeoxycholic acid does not affect the clinical outcome of SARS-CoV-2 infection: a retrospective study of propensity score-matched cohorts, Liver Int
Neuraz, Lerner, Digan, Natural language processing for rapid response to emergent diseases: case study of calcium channel blockers and hypertension in the COVID-19 pandemic, J Med Internet Res
Zecher, Buescher, Willemse, Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: a patient-oriented online survey, United Eur Gastroenterol J
{ 'indexed': {'date-parts': [[2024, 1, 20]], 'date-time': '2024-01-20T00:26:19Z', 'timestamp': 1705710379938},
'reference-count': 12,
'publisher': 'Wiley',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2024, 1, 19]],
'date-time': '2024-01-19T00:00:00Z',
'timestamp': 1705622400000},
'content-version': 'vor',
'delay-in-days': 18,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 1]]},
'abstract': '<jats:title>Abstract</jats:title><jats:p>Recent data suggest that ursodeoxycholic acid (UDCA) '
'therapy may reduce susceptibility to severe acute respiratory syndrome coronavirus 2\xa0'
'(SARS‐CoV‐2) infection and even improve clinical outcomes when coronavirus disease‐2019\xa0'
"(COVID‐19) was diagnosed. However, clinical evidence of UDCA's ability to prevent severe "
'forms of COVID‐19 remains limited and contradictory. We evaluated the association between '
'UDCA exposure and the risk of hospitalization for COVID‐19 in a large multicenter population '
'of patients with chronic liver disease (CLD) followed during the pandemic period before '
'vaccination. An exposed/unexposed cohort study and a nested case–control study were '
'performed. The primary endpoint was severe COVID‐19, defined as SARS‐CoV2 infection requiring '
'hospitalization. The secondary endpoint was COVID‐19‐associated intensive care unit (ICU) '
'admission or death. Adjusted odds ratios (aOR) and their confidence intervals (CI) were '
'determined after controlling for age, gender, comorbidities at risk for COVID‐19, severity of '
'CLD, and prior hospitalizations. A total of 10\u2009147 patients, including 1322 exposed and '
'8825 not exposed to UDCA, totaling 21\u2009867 person‐years of follow‐up, were included in '
'the cohort analysis, while 88 patients hospitalized for COVID‐19 and 840 matched controls '
'were eligible for the nested case–control analysis. In both analyses, exposure to UDCA was '
'not associated with a significant reduction in the risk of hospitalization for COVID‐19, with '
'aOR (95% confidence interval) values of 0.48 (0.20–1.19) and 0.93 (0.26–3.29), respectively. '
'Furthermore, there was no significant reduction in the risk of ICU admission or death. In '
'this large population of patients with CLD, UDCA exposure was not associated with a reduced '
'risk of severe COVID‐19.</jats:p>',
'DOI': '10.1002/jmv.29418',
'type': 'journal-article',
'created': {'date-parts': [[2024, 1, 19]], 'date-time': '2024-01-19T12:18:39Z', 'timestamp': 1705666719000},
'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Exploring the impact of ursodeoxycholic acid therapy on COVID‐19 in a real‐word setting',
'prefix': '10.1002',
'volume': '96',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7920-9784',
'authenticated-orcid': False,
'given': 'Christophe',
'family': 'Corpechot',
'sequence': 'first',
'affiliation': [ { 'name': 'Reference Center for Inflammatory Biliary Diseases and '
'Autoimmune Hepatitis, European Reference Network on '
'Hepatological Diseases (ERN Rare‐Liver), Saint‐Antoine Hospital '
'Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France'},
{ 'name': 'Inserm UMR_S938, Saint‐Antoine Research Center Sorbonne '
'University Paris France'}]},
{ 'given': 'Marie',
'family': 'Verdoux',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Research Unit, Direction of Clinical Research, Bicêtre '
'Hospital, AP‐HP Paris‐Saclay University Le Kremlin‐Bicêtre '
'France'}]},
{ 'given': 'Marie',
'family': 'Frank‐Soltysiak',
'sequence': 'additional',
'affiliation': [ { 'name': 'Medical Informatics Department, Bicêtre Hospital, AP‐HP '
'Paris‐Saclay University Le Kremlin‐Bicêtre France'}]},
{ 'given': 'Jean‐Charles',
'family': 'Duclos‐Vallée',
'sequence': 'additional',
'affiliation': [ { 'name': 'Fédération Hospitalo‐Universitaire Hépatinov, Inserm UMR_S 1193, '
'Paul Brousse Hospital, AP‐HP Paris‐Saclay University Villejuif '
'France'}]},
{ 'given': 'Lamiae',
'family': 'Grimaldi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Research Unit, Direction of Clinical Research, Bicêtre '
'Hospital, AP‐HP Paris‐Saclay University Le Kremlin‐Bicêtre '
'France'},
{ 'name': 'Inserm UMR1018 Anti‐Infective Evasion and '
'Pharmacoepidemiology,\xa0Simone Veil School of Medicine '
'Paris‐Saclay University Montigny‐Le‐Bretonneux France'}]}],
'member': '311',
'published-online': {'date-parts': [[2024, 1, 19]]},
'reference': [ {'key': 'e_1_2_10_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-022-05594-0'},
{'key': 'e_1_2_10_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/joim.13630'},
{ 'key': 'e_1_2_10_4_1',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fcimb.2023.1178590',
'article-title': 'Protective effect of ursodeoxycholic acid on COVID‐19 in patients with '
'chronic liver disease',
'volume': '13',
'author': 'Li Y',
'year': '2023',
'journal-title': 'Front Cell Infect Microbiol'},
{ 'key': 'e_1_2_10_5_1',
'doi-asserted-by': 'crossref',
'article-title': 'Effect of ursodeoxycholic acid on preventing SARS‐CoV‐2 infection in '
'patients with liver transplantation: a multicenter retrospective cohort '
'study',
'author': 'Hu L',
'year': '2023',
'journal-title': 'QJM',
'DOI': '10.1093/qjmed/hcad254'},
{ 'issue': '8',
'key': 'e_1_2_10_6_1',
'doi-asserted-by': 'crossref',
'first-page': '1738',
'DOI': '10.3390/v15081738',
'article-title': 'Ursodeoxycholic acid does not improve COVID‐19 outcome in hospitalized '
'patients',
'volume': '15',
'author': 'Colapietro F',
'year': '2023',
'journal-title': 'Viruses'},
{ 'key': 'e_1_2_10_7_1',
'doi-asserted-by': 'crossref',
'first-page': '83',
'DOI': '10.1111/liv.15736',
'article-title': 'Ursodeoxycholic acid does not affect the clinical outcome of SARS‐CoV‐2 '
'infection: a retrospective study of propensity score‐matched cohorts',
'volume': '44',
'author': 'Marrone G',
'year': '2023',
'journal-title': 'Liver Int'},
{'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/liv.15660'},
{'key': 'e_1_2_10_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cmpb.2018.10.016'},
{ 'key': 'e_1_2_10_10_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41746-020-00308-0'},
{'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2196/20773'},
{ 'key': 'e_1_2_10_12_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/gutjnl-2021-325700'},
{'key': 'e_1_2_10_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/ueg2.12100'}],
'container-title': 'Journal of Medical Virology',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.29418',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 1, 19]],
'date-time': '2024-01-19T12:18:43Z',
'timestamp': 1705666723000},
'score': 1,
'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/jmv.29418'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 1]]},
'references-count': 12,
'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2024, 1]]}},
'alternative-id': ['10.1002/jmv.29418'],
'URL': 'http://dx.doi.org/10.1002/jmv.29418',
'relation': {},
'ISSN': ['0146-6615', '1096-9071'],
'subject': ['Infectious Diseases', 'Virology'],
'container-title-short': 'Journal of Medical Virology',
'published': {'date-parts': [[2024, 1]]},
'assertion': [ { 'value': '2023-12-08',
'order': 0,
'name': 'received',
'label': 'Received',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-01-09',
'order': 1,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-01-19',
'order': 2,
'name': 'published',
'label': 'Published',
'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
